Mapping the genetic makeup of ovarian cancer at a single cell level
Transcriptional Map of Ovarian Cancer at the Single Cell Level
This study is trying to understand the different genetic features of ovarian cancer by looking closely at tumor samples from women with the disease to find new ways to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | immunotherapy, bevacizumab, chemotherapy |
| Locations | 1 site (Strasbourg, Alsace) |
| Trial ID | NCT05030805 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a detailed transcriptional map of ovarian cancer by analyzing fresh tumor samples from women diagnosed with the disease. After determining the tumor stage, samples will undergo single cell preparation and sequencing to identify genetic variations and neoantigens. The study will utilize advanced technologies such as the Chromium Controller for library preparation and the NextSeq550 system for sequencing, followed by bioinformatics analysis to explore the transcriptome of different cell populations. The findings may help in understanding cancer heterogeneity and identifying new therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 and older with a confirmed diagnosis of ovarian cancer who have undergone surgery at the Strasbourg University Hospital.
Not a fit: Patients with chronic inflammatory diseases, a history of immunotherapy treatment, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of more effective therapies for ovarian cancer by uncovering new treatment targets.
How similar studies have performed: While the approach of mapping cancer at the single cell level is gaining traction, this specific study's methodology is relatively novel and untested in the context of ovarian cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women of legal age (≥ 18 years) * With an ovarian cancer confirmed by anatomopathological analysis * Operated in the gynecology department of the Strasbourg University Hospital between 2021 and 2024 * Patients having given their agreement to participate in the present trial and to the constitution of the collection of biological samples Exclusion criteria: * Chronic inflammatory disease (Lupus, rheumatoid arthritis, chronic inflammatory bowel disease, etc.) * History of immunotherapy treatment (anti PDL1...) * Previous appendixctomy for another reason * Impossibility to give the patient informed information (subject in an emergency situation, difficulties in understanding, language barrier, altered cognitive abilities) * Patient under legal protection or tutorship or curatorship. * Pregnant patient, breastfeeding * Persons deprived of liberty by judicial or administrative decision. * Persons under forced psychiatric care.
Where this trial is running
Strasbourg, Alsace
- Service Gynécologie Obstétrique, Hôpital de Hautepierre — Strasbourg, Alsace, France (Recruiting)
Study contacts
- Study coordinator: Cherif Akladios, MD
- Email: Cherif.AKLADIOS@chru-strasbourg.fr
- Phone: 3 88 12 74 55
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.